HENDERSON MICHAEL THOMAS — SEC Form 4 filings
SEC reporting owner CIK 1779990. 33 Form 4 filings on record with FilingPulse; latest filed 2026-09-03.
Transaction summary — filings shown
Covers all 33 filings on record, filed 2024-05-16 to 2026-09-03. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 55 legs across 22 filings — 605,000 shares, $45,909,546 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 17.
- Largest priced transaction: sale of 80,000 shares @ $132.54 ($10,603,200) in Apogee Therapeutics, Inc., filed 2026-06-24.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Apogee Therapeutics, Inc. (APGE) | Chief Executive Officer, Director | 25 | — | 50 legs · 505,000 sh · $37,957,496 | 11 |
| Spyre Therapeutics, Inc. (SYRE) | Director | 7 | — | 5 legs · 100,000 sh · $7,952,050 | 5 |
| ARYA Sciences Acquisition Corp IV (ARYD) | Director | 1 | — | — | 1 |
Form 4 filings — HENDERSON MICHAEL THOMAS
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-03 | 4 | Apogee Therapeutics, Inc. (APGE) | Disposition to issuer (D): 920,941 · Disposition to issuer (D): 387,012 (derivative) · Disposition to issuer (D): 357,036 (derivative) · Disposition to issuer (D): 253,016 (derivative) | EDGAR |
| 2026-07-10 | 4 | Apogee Therapeutics, Inc. (APGE) | Sale (S): 20,000 @ $133.63 · Gift (G): 75,046 @ $0 | EDGAR |
| 2026-06-24 | 4 | Apogee Therapeutics, Inc. (APGE) | Sale (S): 80,000 @ $132.54 | EDGAR |
| 2026-06-23 | 4 | Spyre Therapeutics, Inc. (SYRE) | Sale (S): 20,000 @ $100 | EDGAR |
| 2026-06-12 | 4 | Apogee Therapeutics, Inc. (APGE) | Sale (S): 6,770 @ $82.21 · Sale (S): 7,654 @ $82.78 · Sale (S): 1,080 @ $84.18 · Sale (S): 1,577 @ $85.19 · Sale (S): 2,305 @ $86.27 · Sale (S): 614 @ $86.89 | EDGAR |
| 2026-05-29 | 4 | Spyre Therapeutics, Inc. (SYRE) | Grant/award (A): 8,026 (derivative) @ $0 | EDGAR |
| 2026-05-15 | 4 | Apogee Therapeutics, Inc. (APGE) | Sale (S): 18,659 @ $82.05 · Sale (S): 1,341 @ $82.58 | EDGAR |
| 2026-05-08 | 4 | Spyre Therapeutics, Inc. (SYRE) | Sale (S): 2,404 @ $72.57 · Sale (S): 33,513 @ $73.72 · Sale (S): 24,814 @ $74.76 · Sale (S): 19,269 @ $75.35 | EDGAR |
| 2026-04-20 | 4 | Apogee Therapeutics, Inc. (APGE) | Option exercise (M): 3,000 @ $22.86 · Option exercise (M): 3,000 (derivative) @ $0 | EDGAR |
| 2026-04-10 | 4 | Apogee Therapeutics, Inc. (APGE) | Sale (S): 17,800 @ $82.48 · Sale (S): 2,000 @ $83.26 · Sale (S): 200 @ $85 | EDGAR |
| 2026-03-13 | 4 | Apogee Therapeutics, Inc. (APGE) | Sale (S): 8,363 @ $74.29 · Sale (S): 8,219 @ $74.83 · Sale (S): 3,418 @ $75.86 | EDGAR |
| 2026-02-13 | 4 | Apogee Therapeutics, Inc. (APGE) | Sale (S): 11,494 @ $62.96 · Sale (S): 7,551 @ $63.73 · Sale (S): 955 @ $64.99 | EDGAR |
| 2026-01-23 | 4 | Spyre Therapeutics, Inc. (SYRE) | Other (J): 63,227 @ $0 | EDGAR |
| 2026-01-16 | 4 | Apogee Therapeutics, Inc. (APGE) | Sale (S): 1,440 @ $78.64 · Sale (S): 8,476 @ $79.82 · Sale (S): 2,374 @ $81 · Sale (S): 1,854 @ $82.41 · Sale (S): 5,386 @ $83.16 · Sale (S): 470 @ $83.79 | EDGAR |
| 2026-01-06 | 4 | Apogee Therapeutics, Inc. (APGE) | Grant/award (A): 253,016 (derivative) @ $0 | EDGAR |
| 2025-12-12 | 4 | Apogee Therapeutics, Inc. (APGE) | Sale (S): 9,435 @ $74.88 · Sale (S): 10,005 @ $75.79 · Sale (S): 560 @ $76.58 | EDGAR |
| 2025-12-05 | 4 | Apogee Therapeutics, Inc. (APGE) | Sale (S): 40,000 @ $75.01 | EDGAR |
| 2025-11-13 | 4 | Apogee Therapeutics, Inc. (APGE) | Sale (S): 3,340 @ $61.93 · Sale (S): 14,774 @ $63.14 · Sale (S): 1,786 @ $63.89 · Sale (S): 100 @ $64.52 | EDGAR |
| 2025-06-02 | 4 | Spyre Therapeutics, Inc. (SYRE) | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-03-07 | 4 | Apogee Therapeutics, Inc. (APGE) | Sale (S): 7,326 @ $29.98 · Sale (S): 2,674 @ $30.62 | EDGAR |
| 2025-02-07 | 4 | Apogee Therapeutics, Inc. (APGE) | Sale (S): 15,000 @ $40.58 | EDGAR |
| 2025-01-31 | 4 | Apogee Therapeutics, Inc. (APGE) | Option exercise (M): 8,500 @ $22.86 · Option exercise (M): 8,500 (derivative) @ $0 | EDGAR |
| 2025-01-14 | 4 | Spyre Therapeutics, Inc. (SYRE) | Other (J): 105,379 @ $0 | EDGAR |
| 2025-01-10 | 4 | Apogee Therapeutics, Inc. (APGE) | Sale (S): 12,132 @ $48.72 · Sale (S): 2,868 @ $49.38 | EDGAR |
| 2024-12-11 | 4 | Apogee Therapeutics, Inc. (APGE) | Grant/award (A): 357,036 (derivative) @ $0 | EDGAR |
| 2024-12-06 | 4 | Apogee Therapeutics, Inc. (APGE) | Sale (S): 13,328 @ $46.50 · Sale (S): 1,672 @ $47.19 | EDGAR |
| 2024-11-08 | 4 | Apogee Therapeutics, Inc. (APGE) | Sale (S): 14,000 @ $59.17 · Sale (S): 1,000 @ $59.94 | EDGAR |
| 2024-10-04 | 4 | Apogee Therapeutics, Inc. (APGE) | Sale (S): 30,288 @ $56.07 · Sale (S): 9,712 @ $56.74 | EDGAR |
| 2024-09-06 | 4 | Apogee Therapeutics, Inc. (APGE) | Sale (S): 25,641 @ $47.28 · Sale (S): 14,359 @ $48.23 | EDGAR |
| 2024-08-09 | 4 | Apogee Therapeutics, Inc. (APGE) | Sale (S): 32,233 @ $40.40 · Sale (S): 7,667 @ $41.52 · Sale (S): 100 @ $42.17 | EDGAR |
| 2024-07-31 | 4 | ARYA Sciences Acquisition Corp IV (ARYD) | Disposition to issuer (D): 30,000 (derivative) | EDGAR |
| 2024-07-05 | 4 | Apogee Therapeutics, Inc. (APGE) | Sale (S): 15,000 @ $37.26 | EDGAR |
| 2024-05-16 | 4 | Spyre Therapeutics, Inc. (SYRE) | Grant/award (A): 11,323 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1779990 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →